Do we understand the pathophysiology of endometrial cancer?

Endometrial carcinoma is the fourth most common cancer in UK women. Previous literature describes local, haematological or lymphatic dissemination to common sites including vaginal vault, lungs, liver, bones and brain. The authors present two unusual cases of endometrial cancer metastases to the psoas major muscle and laparoscopic port sites. Case 1 involves a 71-year-old female who underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy and peritoneal washings (TAH, BSO, PW) for Grade 1 endometrial cancer, Stage 1B. Three years later she represented with lower back and right hip pain, with MRI imaging revealing psoas muscle metastases. Case 2 describes a 60-year-old female who underwent laparoscopic-assisted vaginal hysterectomy (LAVH), BSO+ PW for Grade 1 endometrial cancer, Stage 1B. Three years postoperatively she presented with a lateral abdominal mass overlying the laparoscopic port site scar, which was Grade 1 endometrial cancer on biopsy. These rare metastatic locations question our traditional understanding of the pathophysiology of endometrial carcinoma.

Endometrial cancer; Dissemination; Psoas major muscle; Laparoscopic port site.

[1] National Cancer Institute: “Endometrial cancer treatment PDQ; Gen-eral information about endometrial cancer; 2014”. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/endometrial/Heal thProfessional/page1

[2] Creasman W.T., Odicino F., Maisonneuve P., Quinn M.A., Beller U., Benedet J.L., et al.: “Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer”. Int. J. Gynaecol. Obstet., 2006, 95, S105.

[3] Cancer Research UK: “Cancer statistics; Endometrial Cancer”. London: Cancer Research U.K, 2011.

[4] Bokhman J.V.: “Two pathogenetic types of endometrial carcinoma”. Gynecol. Oncol., 1983, 15, 10.

[5] Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I.: “Endometrial cancer”. Lancet, 2005, 366, 491.

[6] AlHilli M.M., Mariani A.: “The role of paraaortic lymphadenec-tomy in endometrial cancer”. Int. J. Clin. Oncol., 2013, 18, 193.

[7] Morgan-Parkes J.H.: “Metastases: mechanisms, pathways, and cascades”. AJR Am. J. Roentgenol., 1995, 164, 1075.

[8] Faught W., Fung Kee Fung M.: “Port site recurrences following la-paroscopically managed early stage endometrial cancer”. Int. J. Gy-necol. Cancer, 1999, 9, 256.

[9] Kadar N.: “Port-site recurrences following laparoscopic operations for gynaecological malignancies”. Br. J. Obstet. Gynaecol., 1997, 104, 1308.

[10] Kim B., Huh S.J., Kim B.G.: “Port site metastasis after robotic-as-sisted laparoscopic hysterectomy for uterine cervical cancer: a case report and literature review”. Taiwan J. Obstet. Gynecol., 2013, 52, 558.

[11] Lönnerfors C., Bossmar T., Persson J.: “Portsite metastases follow-ing robot-assisted laparoscopic surgery for gynecological malignancies”. Acta Obstet. Gynecol. Scand., 2013, 92, 1361.

[12] Martínez A., Querleu D., Leblanc E., Narducci F., Ferron G.: “Low incidence of port-site metastases after laparoscopic staging of uterine cancer”. Gynecol. Oncol., 2010, 118, 145.

[13] Muntz H.G., Goff B.A., Madsen B.L., Yon J.L.: “Port-site recurrence after laparoscopic surgery for endometrial carcinoma”. Obstet. Gy-necol., 1999, 93, 807.

[14] Nagarsheth N.P., Rahaman J., Cohen C.J., Gretz H., Nezhat F.: “The incidence of port-site metastases in gynecologic cancers”. JSLS, 2004, 8, 133.

[15] Ndofor B.T., Soliman P.T., Schmeler K.M., Nick A.M., Frumovitz M., Ramirez P.T.: “Rate of port-site metastasis is uncommon in pa-tients undergoing robotic surgery for gynecological malignancies”. Int. J. Gynecol. Cancer, 2011, 21, 936.

[16] Rauff S., Ng J.S.: “Portsite recurrence in a patient undergoing robot-assisted gynecologic cancer surgery for endometrial cancer - A case report”. Gynecol. Oncol. Case Rep., 2012, 2, 127.

[17] Sanjuán A., Hernández S., Pahisa J., Ayuso J.R., Torné A., Martínez Román S., et al.: “Port-site metastasis after laparoscopic surgery for endometrial carcinoma: two case reports”. Gynecol. Oncol., 2005, 96, 539.

[18] Wang P.H., Yen M.S., Yuan C.C., Chao K.C., Ng H.T., Lee W.L., et al.: “Port site metastasis after laparoscopic-assisted vaginal hysterectomy for endometrial cancer: possible mechanisms and pre-vention”. Gynecol. Oncol., 1997, 66, 151.

[19] Wang P.H., Yuan C.C., Lin G., Ng H.T., Chao H.T.: “Risk factors contributing to early occurrence of port site metastases of laparoscopic surgery for malignancy”. Gynecol. Oncol., 1999, 72, 38.

[20] Thomas C.G.: “Tumor cell contamination of the surgical wound: experimental and clinical observations”. Ann. Surg., 1961, 153, 697.

[21] Sugarbaker P.H., Cunliffe W.J., Belliveau J., de Bruijn E.A., Graves T., Mullins R.E., et al.: “Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gas-trointestinal cancer”. Semin. Oncol., 1989, 16, 83.

[22] Stewart C.J., Doherty D.A., Havlat M., Koay M.H., Leung Y.C., Naran A., et al.: “Transtubal spread of endometrial carcinoma: correlation of intraluminal tumour cells with tumour grade, peritoneal fluid cytol-ogy, and extra-uterine metastasis”. Pathology, 2013, 45, 382.

[23] Soslow R.A., Pirog E., Isacson C.: “Endometrial intraepithelial car-cinoma with associated peritoneal carcinomatosis”. Am. J. Surg. Pathol., 2000, 24, 726.

[24] Abeler V.M., Vergote I.B., Kjørstad K.E., Tropé C.G.: “Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern”. Cancer, 1996, 78, 1740.

[25] Revel A., Tsafrir A., Anteby S.O., Shushan A.: “Does hysteroscopy produce intraperitoneal spread of endometrial cancer cells?” Obstet. Gynecol. Surv., 2004, 59, 280.

[26] Obermair A., Geramou M., Gücer F., Denison U., Graf A.H., Kap-shammer E., et al.: “Impact of hysteroscopy on disease-free survival in clinically stage I endometrial cancer patients”. Int. J. Gynecol. Cancer, 2000, 10, 275.

[27] Takac I., Zegura B.: “Office hysteroscopy and the risk of microscopic extrauterine spread in endometrial cancer”. Gynecol. Oncol., 2007, 107, 94.

[28] Zerbe M.J., Zhang J., Bristow R.E., Grumbine F.C., Abularach S., Montz F.J.: “Retrograde seeding of malignant cells during hysteroscopy in presumed early endometrial cancer”. Gynecol. Oncol., 2000, 79, 55.

[29] Djurdjević S., Mladenović-Segedi L., Djolai M.: “Endometrical can-cer metastases in the region of abdominal muscles and pelvic wall”. J. BUON., 2006, 11, 75.

[30] Neuhaus S.J., Watson D.I., Ellis T., Dodd T., Rofe A.M., Jamieson G. G.: “Efficacy of cytotoxic agents for the prevention of laparo-scopic port-site metastases”. Arch. Surg., 1998, 133, 762.

[31] Santeufemia D.A., Lumachi F., Basso S.M., Tumolo S., Re G.L., Capobianco G., et al.: “Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy as salvage treatment for a late wound recurrence of endometrial cancer”. Anticancer Res., 2013, 33, 1041.

[32] Galaal K., Bryant A., Fisher A.D., Al-Khaduri M., Kew F., Lopes A.D.: “Laparoscopy versus laparotomy for the management of early stage endometrial cancer”. Cochrane Database Syst. Rev., 2012, 9. CD006655. doi: 10.1002/14651858.CD006655.pub2.

[33] Mo X., Yang Y., Lai H., Xiao J., He K., Chen J., Lin Y.: “Does car-bon dioxide pneumoperitoneum enhance wound metastases following laparoscopic abdominal tumor surgery? A meta-analysis of 20 randomized control studies”. Tumour Biol., 2014, 35, 7351. doi: 10.1007/s13277-014-1812-5. Epub 2014 Apr 18.

[34] Kuhry E., Schwenk W., Gaupset R., Romild U., Bonjer J.: “Long-term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials”. Cancer Treat. Rev., 2008, 34, 498.